Stockscreener 앱 받기
7.06
6.17%
0.41
시장 영업 전:
7.06
전일 마감가:
$6.65
열려 있는:
$6.81
하루 거래량:
494.31K
Relative Volume:
0.97
시가총액:
$200.67M
수익:
$67.22M
순이익/손실:
$-65.78M
주가수익비율:
-2.9581
EPS:
-2.3867
순현금흐름:
$-79.02M
1주 성능:
+7.79%
1개월 성능:
-14.94%
6개월 성능:
-65.24%
1년 성능:
-44.71%
1일 변동 폭
$6.80
$7.17
1주일 범위
$6.40
$7.17
52주 변동 폭
$5.85
$24.17
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
명칭
Arcturus Therapeutics Holdings Inc
전화
(858) 900-2660
주소
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare ARCT vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
7.06 | 200.67M | 67.22M | -65.78M | -79.02M | -2.3867 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 개시 | B. Riley Securities | Buy |
| 2026-01-23 | 개시 | Roth Capital | Buy |
| 2025-10-24 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-10-23 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-10-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-09-04 | 재개 | H.C. Wainwright | Buy |
| 2025-05-28 | 개시 | Scotiabank | Sector Outperform |
| 2025-01-28 | 개시 | BTIG Research | Buy |
| 2024-08-12 | 개시 | Leerink Partners | Outperform |
| 2023-12-13 | 개시 | Canaccord Genuity | Buy |
| 2023-07-24 | 개시 | William Blair | Outperform |
| 2023-05-11 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-11-14 | 재개 | Wells Fargo | Overweight |
| 2022-11-10 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2022-11-03 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-11-02 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-08-10 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-07-19 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-05-11 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2022-04-21 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-01-31 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2021-08-12 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2021-08-11 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-08-10 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2021-07-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-06-25 | 재개 | Goldman | Neutral |
| 2021-06-21 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-02-17 | 다운그레이드 | B. Riley Securities | Neutral → Sell |
| 2021-01-19 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-01-15 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-01-07 | 개시 | Wells Fargo | Overweight |
| 2020-12-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-12-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-12-29 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-12-29 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-23 | 다운그레이드 | ROTH Capital | Buy → Sell |
| 2020-12-08 | 재확인 | B. Riley Securities | Buy |
| 2020-12-07 | 재확인 | B. Riley Securities | Buy |
| 2020-10-26 | 개시 | Barclays | Overweight |
| 2020-10-06 | 개시 | Citigroup | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-07-30 | 재개 | ROTH Capital | Buy |
| 2020-07-16 | 개시 | Raymond James | Outperform |
| 2020-07-13 | 개시 | B. Riley FBR | Buy |
| 2020-06-09 | 다운그레이드 | WBB Securities | Buy → Hold |
| 2020-02-11 | 개시 | Robert W. Baird | Outperform |
| 2020-02-07 | 개시 | Guggenheim | Buy |
| 2020-02-06 | 개시 | Guggenheim | Buy |
| 2019-04-05 | 개시 | H.C. Wainwright | Buy |
| 2018-09-20 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2018-01-22 | 개시 | Chardan Capital Markets | Buy |
모두보기
Arcturus Therapeutics Holdings Inc 주식(ARCT)의 최신 뉴스
Understanding the Setup: (ARCT) and Scalable Risk - Stock Traders Daily
Arcturus Therapeutics Refocuses on Rare Disease mRNA Pipeline After COVID Vaccine Success at ROTH Conf - MarketBeat
Arcturus Therapeutics at the 38th Annual Roth Conference: Strategic Shift to Rare Diseases - Investing.com Canada
These Are the Only 3 Stocks That Cathie Wood Bought Last Week - The Motley Fool
Arcturus Therapeutics stock plunges 50% after weak cystic fibrosis trial data - MSN
ARCT Stock Price, Quote & Chart | ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) - ChartMill
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2025 earnings call transcript - MSN
This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday - Benzinga
Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Upgraded by B. Riley Financial - MarketBeat
This BP Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Friday - Benzinga
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
This Xponential Fitness Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga
This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
This Union Pacific Analyst Turns Bullish; Here Are Top 3 Upgrades For Wednesday - Benzinga
B Riley Securities initiates coverage of Arcturus Therapeutics Holdings (ARCT) with buy recommendation - MSN
Cathie Wood’s ARK sells Guardant Health stock, buys Arcturus Therapeutics - Investing.com
Cathie Wood’s ARK sells Guardant Health stock, buys Arcturus Therapeutics By Investing.com - Investing.com Australia
Arcturus Therapeutics (NASDAQ:ARCT) Coverage Initiated at B. Riley Financial - MarketBeat
This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
ARCT: B. Riley Securities Initiates Coverage with 'Buy' Rating | - GuruFocus
Arcturus Therapeutics stresses importance of phased clinical trials in drug development - Traders Union
Update Recap: How is Arcturus Therapeutics Holdings Inc managing supply chain issuesWeekly Stock Summary & Short-Term Swing Trade Alerts - baoquankhu1.vn
Can Arcturus Therapeutics Holdings Inc sustain its profitabilityMarket Sentiment Review & Reliable Entry Point Alerts - baoquankhu1.vn
The Technical Signals Behind (ARCT) That Institutions Follow - Stock Traders Daily
Arcturus Therapeutics Teases 12-Week Phase 2 CF Study After Well-Tolerated Inhaled mRNA Dosing - MarketBeat
Patients and scientists join forces for rare disease progress, Arcturus Therapeutics asserts - Traders Union
ARCT Should I Buy - Intellectia AI
Arcturus (ARCT) Q4 2025 Earnings Call Transcript - AOL.com
Stock Report: Can Arcturus Therapeutics Holdings Inc sustain its profitabilityJuly 2025 Fed Impact & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Arcturus Therapeutics: Downgrading to "Hold" As CF Program Shifts Population Focus (ARCT) - Seeking Alpha
Arcturus Therapeutics to attend Leerink Partners 2026 Global Healthcare Conference - Traders Union
Q1 EPS Forecast for Arcturus Therapeutics Reduced by Analyst - MarketBeat
Demystifying Arcturus Therapeutics: Insights From 4 Analyst Reviews - Benzinga
Citigroup Lowers Price Target for Arcturus Therapeutics (ARCT) t - GuruFocus
Citigroup Issues Pessimistic Forecast for Arcturus Therapeutics (NASDAQ:ARCT) Stock Price - MarketBeat
Arcturus Therapeutics to Attend Upcoming Investor Conference - PharmiWeb.com
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2025 Earnings Call Transcript - Insider Monkey
ARK Investment Management LLC Boosts Position in Arcturus Therapeutics Holdings Inc. $ARCT - MarketBeat
Piper Sandler Maintains Overweight on Arcturus Therapeutics (ARCT) March 2026 - Meyka
Gossamer Bio, Seralutinib Misses Tight Statistical Mark But Shows Heart In High-Risk Lung Disease Study - AOL.com
Arcturus Therapeutics Holdings ARCT Q4 Revenue Slide To US$7.2 Million Tests Growth Narrative - simplywall.st
Arcturus Therapeutics Holdings Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Citigroup Issues Positive Forecast for Arcturus Therapeutics (NASDAQ:ARCT) Stock Price - MarketBeat
Citigroup Raises Price Target for Arcturus Therapeutics (ARCT) t - GuruFocus
Piper Sandler Lowers Price Target for Arcturus Therapeutics (ARC - GuruFocus
New nasal vaccine protects lungs for months against viruses, bacteria, and allergens - AOL.com
Piper Sandler Cuts Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $25.00 - MarketBeat
Arcturus Therapeutics reports financial results and pipeline progress - Traders Union
Arcturus Therapeutics Holdings Inc (ARCT) Q4 2025 Earnings Call - GuruFocus
Arcturus Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline P - PharmiWeb.com
Arcturus Therapeutics Holdings Inc (ARCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):